

OFFICE OF LEGISLATIVE RESEARCH  
PUBLIC ACT SUMMARY



**PA 25-63—SB 1473**

*Human Services Committee*

**AN ACT REQUIRING MEDICAID COVERAGE FOR FDA-APPROVED  
GENE THERAPIES TO TREAT SICKLE CELL DISEASE**

**SUMMARY:** This act requires the Department of Social Services commissioner to provide Medicaid coverage for federal Food and Drug Administration (FDA)-approved gene therapies to treat sickle cell disease. (Federal law generally requires Medicaid to cover these therapies from manufacturers participating in the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8).) The commissioner must apply for any federal initiative, including the Centers for Medicare and Medicaid Services' cell and gene therapy access model, to increase cost-effective access to these therapies (which conforms to current practice).

The commissioner must report, by January 1, 2026, to the Human Services Committee on (1) efforts to increase cost-effective access to the therapies, (2) the number of Medicaid recipients who received Medicaid-covered therapies and the state's cost to cover them, and (3) estimated state appropriations needed for this coverage.

EFFECTIVE DATE: Upon passage